Migraine affects over a billion people, yet its cellular mechanisms remain unclear. This research studies how CGRP-blocking drugs interact with two key receptors—CGRP and AMY1—to understand why treatments help some patients but not others. The findings may guide development of more effective, targeted migraine therapies and reduce debilitating attacks.